Neil K. Warma
I-Mab Biopharma announced the appointment of Neil K. Warma as General Manager of I-Mab Biopharma U.S., on September 3rd. Warma will lead the Company's effort to expand the R&D and business operations in the U.S.
Warma has over 25 years of experience in the healthcare industry across the globe. Prior to joining I-Mab, he was President and CEO of Opexa Therapeutics, where he led the development of the company's personalized cell therapy platform and oversaw its advance through clinical development. Warma also held key management roles at Novartis as Head of Global Pharma Policy and in Global Marketing. In the years before, he was the CEO of Viron Therapeutics, and, prior to that was President and Co-founder of MedExact.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
"We are very excited to have Neil in our executive team at this critical juncture of the Company's rapid development to grow the global presence," said Dr. Jingwu Zang, Founder and Chairman at I-Mab. "Neil's extensive global experiences and proven track record in the pharma and biotech industry will greatly strengthen our global capabilities and leadership to become a global player in our journey moving toward a fully-integrated, global biopharmaceutical company."
"I am thrilled to join I-Mab, an innovative biopharmaceutical company with a successful track record and reputation for advancing transformational medicines with First-in-Class and Best-in-Class potential," Warma said. "I-Mab has a very exciting and rich pipeline of novel drug candidates, with several in late-stage clinical development. Expansion of the business in the U.S. and globally is a natural evolution for I-Mab and I look forward to leading these efforts."
Warma obtained an honors degree specializing in neuroscience from the University of Toronto and an International MBA from the Schulich School of Business at York University in Toronto.